Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-Checkpoint Inhibitor Treatment for Malignant Melanoma

In Vivo - Greece
doi 10.21873/invivo.11244
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Anticancer Research USA Inc.

Related search

Annexin A5 as an Immune Checkpoint Inhibitor and Tumor-Homing Molecule for Cancer Treatment

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2020English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

75 Transient Growth Hormone Deficiency During Bromocryptine Treatment for Hyperprolcatinemia

Pediatric Research
Child HealthPediatricsPerinatology
1988English

Combination VEGFR/immune Checkpoint Inhibitor Therapy: A Promising New Treatment for Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2018English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

H3K27me3 and EZH2 Expression in Melanoma: Relevance for Melanoma Progression and Response to Immune Checkpoint Blockade

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy